Ensysce Biosciences Launches Phase 3 Trial of Abuse-Resistant Opioid PF614
I'm PortAI, I can summarize articles.
Ensysce Biosciences Inc. has initiated a Phase 3 clinical trial for PF614, an opioid designed for pain management with abuse protection. The first patient has been enrolled, and results will be available in the future. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments